Breaking News Instant updates and real-time market news.

2019-04-18 07:53:51 ALKS Alkermes $33.22 -0.96 (-2.81%) 07:53 04/18/19 04/18 07:53 04/18/19 07:53	Alkermes shares trading near base business value, says JPMorgan Ahead of his conference call today with CEO Richard Pops, JPMorgan analyst Cory Kasimov says shares of Alkermes are trading near the company's base business value of $33 and that fundamental downside risk at these levels is "relatively limited." What is harder to determine is whether Alkermes shares will remain range bound for a prolonged period of time or if the company will start to get credit for its later stage product candidates, Kasimov tells investors in a research note. The analyst believes ALKS 3831 and Vumerity are "worth something at this juncture" and that improving investor sentiment will be key, along with solid execution in the near term, to unlock this potential value. He maintains an Overweight rating on Alkermes with a $41 price target.	18 Apr
ALKS Alkermes $33.22 -0.96 (-2.81%) 04/09/19 PIPR 04/09/19 NO CHANGE Target $32 PIPR Neutral Alkermes' ALPINE data an incremental positive, says Piper Jaffray After Alkermes (ALKS) reported this morning that its ALPINE trial met its primary endpoint and that Aristada showed similar efficacy to the current market leader, Invega Sustenna, at all time points assessed, Piper Jaffray analyst Danielle Brill said she views the data as an incremental positive. However, she thinks it will be challenging to capture share from Johnson & Johnson (JNJ), telling investors that she is "not sure these data will be enough to move the needle." Brill maintains a Neutral rating on Alkermes. 04/12/19 GSCO 04/12/19 NO CHANGE Target $27 GSCO Sell Goldman still thinks ALKS 3831 is 'unlikely to be practice changing' After Alkermes presented additional details on efficacy and safety, as well as the first look at the metabolic data from the Enlighten-2 trial and interim data from the ongoing extension study, Goldman Sachs analyst Terence Flynn continues to believe the company's schizophrenia drug ALKS 3831 is "unlikely to be practice changing." The analyst reiterates a Sell rating on the shares with a $27 price target. ALKS 3831 demonstrated a comparable metabolic profile relative to Zyprexa over the 24-week portion of the trial, Flynn tells investors in a research note. The analyst believes an outstanding question remains with respect to potential long term type 2 diabetes risk. It is unclear if the existing ALKS 3831 data will be enough to drive a differentiated label for the drug versus Zyprexa in this regard, which could have commercial implications, says the analyst. 04/12/19 PIPR 04/12/19 NO CHANGE Target $32 PIPR Neutral Alkermes' ALKS-3831 ph3 data saw negligible relative benefit, says Piper Jaffray Piper Jaffray analyst Danielle Brill kept her Neutral rating and $32 price target on Alkermes after its Phase 3 schizophrenia trial data for ALKS-3831 presented at SIRS conference. The analyst says the results showed some "beneficial impacts on weight gain with '3831" when patients switched from olanzapine, but the benefit on metabolic parameters was negligible. Brill states that Alkermes management intends to file a new drug application for '3831 by mid-2019, and while she believes the data support approval, she questions the program's "overall commercial opportunity" relative to other available agents with "more benign safety profiles." 04/15/19 JEFF 04/15/19 NO CHANGE Target $36 JEFF Hold ALKS 3831 could see initial use in olanzapine patients, says Jefferies Jefferies analyst Biren Amin says the key opinion leaders he spoke to indicate ALKS 3831 could see initial use and uptake in patents already on olanzapine but that the drug's use will be limited. Key opinion leaders found the absolute four pound decrease at six months between the two treatment groups to be lacking, with a desire for a minimum of 10 pounds or greater in average weight decrease in patients that were on 3831 versus olanzapine, Amin tells investors in a research note. Further, regarding the drug's metabolic profile, since no change in lipid or glucose profile was observed and given that the study wasn't powered to detect a difference between treatment arms, the data was not considered meaningful by most opinion leaders, adds the analyst. His base case puts ALKS 3831 peak sales at $500M. Amin keeps a Hold rating on Alkermes with a $36 price target.

2019-04-18 07:53:51

ALKS

Alkermes

$33.22: -0.96 (-2.81%)

07:53

04/18/19

04/18

07:53

04/18/19

07:53

Alkermes shares trading near base business value, says JPMorgan

Ahead of his conference call today with CEO Richard Pops, JPMorgan analyst Cory Kasimov says shares of Alkermes are trading near the company's base business value of $33 and that fundamental downside risk at these levels is "relatively limited." What is harder to determine is whether Alkermes shares will remain range bound for a prolonged period of time or if the company will start to get credit for its later stage product candidates, Kasimov tells investors in a research note. The analyst believes ALKS 3831 and Vumerity are "worth something at this juncture" and that improving investor sentiment will be key, along with solid execution in the near term, to unlock this potential value. He maintains an Overweight rating on Alkermes with a $41 price target.

18
Apr

ALKS Alkermes

$33.22: -0.96 (-2.81%)

04/09/19: PIPR

04/12/19: GSCO

04/12/19: PIPR

04/15/19: JEFF

TODAY'S FREE FLY STORIES

KHC Kraft Heinz $31.59 -0.29 (-0.91%) 17:39 12/11/19 12/11 17:39 12/11/19 17:39 Initiation	Kraft Heinz initiated » Kraft Heinz resumed with… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
K Kellogg $66.17 -0.48 (-0.72%) 17:37 12/11/19 12/11 17:37 12/11/19 17:37 Initiation	Kellogg initiated » Kellogg resumed with a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
FCAU Fiat Chrysler $14.32 -0.085 (-0.59%) 17:34 12/11/19 12/11 17:34 12/11/19 17:34 Hot Stocks	UAW ratifies CBA with Fiat Chrysler » UAW Fiat Chrysler U.S.… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Jan
FLO Flowers Foods $21.54 -0.04 (-0.19%) 17:27 12/11/19 12/11 17:27 12/11/19 17:27 Initiation	Flowers Foods initiated » Flowers Foods resumed… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
17:25 12/11/19 12/11 17:25 12/11/19 17:25 General news	U.S. Treasury posted a -$208.8 B budget deficit in November » U.S. Treasury posted a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial

NOMD Nomad Foods $20.54 -0.12 (-0.58%) 17:23 12/11/19 12/11 17:23 12/11/19 17:23 Initiation	Nomad Foods initiated » Nomad Foods resumed with… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
LMPX LMP Automotive $15.05 1.75 (13.16%) 17:23 12/11/19 12/11 17:23 12/11/19 17:23 Hot Stocks	LMP Automotive Chairman Samer Tawfik buys over $1.7M in company shares » LMP Automotive Chairman… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
TGI Triumph Group $28.91 0.1 (0.35%) 17:21 12/11/19 12/11 17:21 12/11/19 17:21 Syndicate	Breaking Syndicate news story on Triumph Group » Triumph Group files to… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
MKC McCormick $170.70 -0.635 (-0.37%) 17:12 12/11/19 12/11 17:12 12/11/19 17:12 Initiation	McCormick initiated » McCormick resumed with a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
CLR Continental Resources $33.37 0.27 (0.82%) 17:10 12/11/19 12/11 17:10 12/11/19 17:10 Conference/Events	Continental Resources to host conference call » Conference call to… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

GIS General Mills $51.57 -1.67 (-3.14%) , K Kellogg $66.17 -0.48 (-0.72%) 17:08 12/11/19 12/11 17:08 12/11/19 17:08 Initiation	General Mills, Kellogg initiated » General Mills resumed… GIS General Mills $51.57 -1.67 (-3.14%) K Kellogg $66.17 -0.48 (-0.72%) Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	18 Dec
CEI Camber Energy $2.05 0.86 (72.27%) 17:05 12/11/19 12/11 17:05 12/11/19 17:05 Hot Stocks	Camber Energy responds to unusual market activity » Camber Energy commented… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
MGEN Miragen Therapeutics $0.69 0.0554 (8.73%) 17:04 12/11/19 12/11 17:04 12/11/19 17:04 Conference/Events	Miragen Therapeutics to host conference call » Conference call to… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
AGI Alamos Gold $5.57 0.205 (3.82%) 17:03 12/11/19 12/11 17:03 12/11/19 17:03 Hot Stocks	Alamos Gold sees FY20 production 425K-465K ounces of gold » Alamos Gold provided 2020… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
MMNFF MedMen $0.00 (0.00%) 17:02 12/11/19 12/11 17:02 12/11/19 17:02 Earnings	MedMen sees positive adjusted EBITDA in Q121, and positive FCF in Q321 » The company anticipates… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	12 Dec

CPB Campbell Soup $48.00 -0.37 (-0.76%) 17:02 12/11/19 12/11 17:02 12/11/19 17:02 Initiation	Campbell Soup initiated » Campbell Soup resumed… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
MMNFF MedMen $0.00 (0.00%) 17:00 12/11/19 12/11 17:00 12/11/19 17:00 Earnings	MedMen sees FY20 revenue $225M - $245M, consensus $212.69M » Sees FY21 revenue $450 -… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	12 Dec
XOM Exxon Mobil $68.95 -0.11 (-0.16%) 16:59 12/11/19 12/11 16:59 12/11/19 16:59 Hot Stocks	Exxon Mobil's Milton sells 13,569 common shares » In a regulatory filing,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	12 Dec
SJM J.M. Smucker $104.42 -1.64 (-1.55%) 16:57 12/11/19 12/11 16:57 12/11/19 16:57 Initiation	J.M. Smucker initiated » J.M. Smucker resumed with… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	26 Feb
16:55 12/11/19 12/11 16:55 12/11/19 16:55 Conference/Events	Oppenheimer healthcare analysts to hold a KOL dinner meeting » Analysts hold a Cardiac… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial

MMNFF MedMen $0.00 (0.00%) 16:54 12/11/19 12/11 16:54 12/11/19 16:54 Hot Stocks	MedMen granted delivery-only license by the city of Mountain View, California » On November 21, the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	12 Dec
CAG Conagra Brands $28.64 -0.58 (-1.98%) 16:53 12/11/19 12/11 16:53 12/11/19 16:53 Initiation	Conagra Brands initiated » Conagra Brands resumed… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	19 Dec
EQH AXA Equitable $24.27 -0.18 (-0.74%) 16:53 12/11/19 12/11 16:53 12/11/19 16:53 Hot Stocks	AXA Equitable sells two run-off and closed-block companies » AXA Equitable has entered… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	11 Dec
MMNFF MedMen $0.00 (0.00%) 16:50 12/11/19 12/11 16:50 12/11/19 16:50 Hot Stocks	MedMen announces financial updates to strengthen balance sheet » MedMen Enterprises… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	12 Dec
MDLZ Mondelez $53.94 -0.13 (-0.24%) 16:48 12/11/19 12/11 16:48 12/11/19 16:48 Initiation	Mondelez initiated » Mondelez resumed with a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Events

Earnings calls, analyst events, roadshows and more

MDP
Today at 18:00

Meredith Firm Sponsored Meetings

New York, NY
VEEV
Today at 21:15

Veeva Firm Sponsored Meetings

Pabu + The Ramen Bar--101 California Street, San Francisco, CA
SPT
Tomorrow at 00:00

Sprout Social - SPT Syndicate Roadshows

New York, NY
Tomorrow at 00:00

Texas Bank Summit Conferences

Texas
CRWD ...
Tomorrow at 00:00

17th Semi-Annual Silicon Valley Technology Bus Tour Conferences

Silicon Valley, CA
Tomorrow at 00:00

Marijuana Business Conference: MJBiz Conferences

Las Vegas Convention Center, Las Vegas, NV
Tomorrow at 00:00

Municipal Outlook Conference Conferences

New York, NY
CADE ...
Tomorrow at 00:00

Atlanta Bank Field Trip Conferences

Atlanta, GA
Tomorrow at 00:00

Enforcement, Litigation & Compliance Conference Conferences

Washington, D.C.
FIVN ...
Tomorrow at 00:00

Global Technology, Media and Telecommunications Conference Conferences

San Francisco, CA

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	CRWD X CRWD Crowdstrike Block Trade Managers: Goldman Sachs Priced at: $49.40 2.2M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AUPH X AUPH Aurinia Pharmaceuticals Secondary Managers: Jefferies & SVB Leerink, H.C. Wainwright, Oppenheimer, Bloom Burton Priced at: $15.00 11.1M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial XAIR X XAIR Beyond Air Secondary Managers: SunTrust, National Securities, Roth Capital, Laidlaw Priced at: $3.66 2.325M Shares ABR X ABR Arbor Realty Spot Secondary Managers: JPMorgan, JMP Securities & Raymond James Priced at: $14.14 6.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CFRX X CFRX ContraFect Spot Secondary Managers: Maxim Priced at: $.27 37.15M Shares RHP X RHP Ryman Hospitality Spot Secondary Managers: BofA/Merrill, JPMorgan & Wells Fargo Priced at: $85.60 3M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SCYX X SCYX Scynexis Spot Secondary Managers: H.C. Wainwright Priced at: $.90 38.89M Shares
Tues	XP X XP XP IPO Managers: Goldman Sachs, JPMorgan, Morgan Stanley, XP & Itau BBA, BofA/Merrill, Citi, Credit Suisse, UBS Priced at: $27.00 72.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CNST X CNST Constellation Pharmaceuticals Spot Secondary Managers: JPMorgan, Jefferies & Cowen, RBC Capital, SunTrust Priced at: $34.50 6.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial GMRE X GMRE Global Medical REIT Spot Secondary Managers: Stifel, BMO Capital, Baird, KeyBanc & SunTrust Priced at: $13.00 6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KIDS X KIDS OrthoPediatrics Spot Secondary Managers: Piper Jaffray & Stifel, BTIG, JMP Securities, SunTrust Priced at: $36.50 1.57M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MDGL X MDGL Madrigal Pharmaceuticals Spot Secondary Managers: Goldman Sachs Priced at: $107.85 1.2M Shares MRNS X MRNS Marinus Pharmaceuticals Spot Secondary Managers: Oppenheimer & Ladenburg Priced at: $1.25 28M Shares PACK X PACK Ranpak Holdings Spot Secondary Managers: Craig-Hallum Priced at: $6.50 15.384M Shares PMT X PMT PennyMac Mortgage Spot Secondary Managers: Morgan Stanley, Credit Suisse, BofA/Merrill, JPMorgan & Barclays, Nomura Instinet, Piper Jaffray Priced at: $22.10 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RCKT X RCKT Rocket Pharmaceuticals Spot Secondary Managers: JPMorgan, Cowen & Evercore ISI, LifeSci Priced at: $22.25 3.82M Shares
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	BILL X BILL Bill.com IPO Managers: Goldman Sachs, BofA/Merrill, Jefferies & KeyBanc, Canaccord, Needham, William Blair $19.00-21.00 8.824M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EH X EH Ehang IPO Managers: Morgan Stanley, Needham, Tigress Financial, Prime Number $12.50-14.50 3.2M Shares LVGO X LVGO Livongo Health Secondary Managers: Morgan Stanley, Goldman Sachs & JPMorgan $27.43 2.78M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MNRL X MNRL Brigham Minerals Secondary Managers: Credit Suisse, Goldman Sachs & RBC Capital $19.70 11M Shares MNTA X MNTA Momenta Secondary Managers: Goldman Sachs & JPMorgan, Stifel $18.07 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ASMB X ASMB Assembly Biosciences Spot Secondary Managers: Jefferies & SVB Leerink $17.71 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FTSV X FTSV Forty Seven Spot Secondary Managers: Morgan Stanley & Credit Suisse $34.00-35.00 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	OCFT X OCFT OneConnect IPO Managers: Morgan Stanley, Goldman Sachs, JPMorgan & Ping An of China, BofA/Merrill, HSBC, CLSA, KeyBanc $9.00-10.00 26M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SPT X SPT Sprout Social IPO Managers: Goldman Sachs, Morgan Stanley, KeyBanc & William Blair, Canaccord, Stifel $16.00-18.00 8.824M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AQST X AQST Aquestive Therapeutics Secondary Managers: BMO Capital $7.51 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PHR X PHR Phreesia Secondary Managers: JPMorgan, Wells Fargo, William Blair, Allen & Co., Piper Jaffray, Baird, Raymond James $28.72 6M Shares
Fri	No deals

View All Syndicate Announcements »

Alkermes shares trading near base business value, says JPMorgan

TODAY'S FREE FLY STORIES

Get Full Fly Access